Amygdalin Blocks Bladder Cancer Cell Growth In Vitro by Diminishing Cyclin A and cdk2
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Amygdalin Blocks Bladder Cancer Cell Growth In Vitro by Diminishing Cyclin A and cdk2
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 8, Pages e105590
Publisher
Public Library of Science (PLoS)
Online
2014-08-20
DOI
10.1371/journal.pone.0105590
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CDK4 inhibition restores G₁-S arrest inMYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage
- (2013) Sina Gogolin et al. CELL CYCLE
- Prospective Evaluation of a Molecular Marker Panel for Prediction of Recurrence and Cancer-specific Survival After Radical Cystectomy
- (2013) Yair Lotan et al. EUROPEAN UROLOGY
- PI3K/AKT pathway activation in bladder carcinogenesis
- (2013) Julien Calderaro et al. INTERNATIONAL JOURNAL OF CANCER
- miR-194 suppresses metastasis of non-small cell lung cancer through regulating expression of BMP1 and p27kip1
- (2013) X Wu et al. ONCOGENE
- Targeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors
- (2013) Todd M. Pitts et al. PHARMACOLOGY & THERAPEUTICS
- Resistance after Chronic Application of the HDAC-Inhibitor Valproic Acid Is Associated with Elevated Akt Activation in Renal Cell Carcinoma In Vivo
- (2013) Eva Juengel et al. PLoS One
- Sesquiterpene Lactones Downregulate G2/M Cell Cycle Regulator Proteins and Affect the Invasive Potential of Human Soft Tissue Sarcoma Cells
- (2013) Birgit Lohberger et al. PLoS One
- Mammalian Target of Rapamycin Complex 2 (mTORC2) Is a Critical Determinant of Bladder Cancer Invasion
- (2013) Sounak Gupta et al. PLoS One
- HuR cytoplasmic expression is associated with increased cyclin A expression and poor outcome with upper urinary tract urothelial carcinoma
- (2012) Peir-In Liang et al. BMC CANCER
- Cyclin dependent kinases in cancer
- (2012) Miriam Canavese et al. CANCER BIOLOGY & THERAPY
- Amygdalin induces apoptosis in human cervical cancer cell line HeLa cells
- (2012) Yu Chen et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Amygdalin inhibits angiogenesis in the cultured endothelial cells of diabetic rats
- (2012) Shahnaz Khaghani et al. Indian Journal of Pathology and Microbiology
- The mTOR Signalling Pathway in Human Cancer
- (2012) Helena Pópulo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Beliefs and Perceptions of Women with Newly Diagnosed Breast Cancer Who Refused Conventional Treatment in Favor of Alternative Therapies
- (2012) D. L. Citrin et al. ONCOLOGIST
- The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line
- (2011) Igor Tsaur et al. CANCER LETTERS
- p27 deficiency is associated with migration defects in PDGF-expressing gliomas in vivo
- (2011) Wendy L. See et al. CELL CYCLE
- Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
- (2009) D. S. Boss et al. ANNALS OF ONCOLOGY
- Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates
- (2009) Brenda K. Edwards et al. CANCER
- Bladder cancer
- (2009) Donald S Kaufman et al. LANCET
- WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells
- (2009) Y. Tang et al. MOLECULAR CANCER THERAPEUTICS
- Distinct Activation Pathways Confer Cyclin-Binding Specificity on Cdk1 and Cdk2 in Human Cells
- (2008) Karl A. Merrick et al. MOLECULAR CELL
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started